Cutaneous Rhizopus infection at a central venous catheter site in a critically ill renal transplant patient
Zoel A. Quiñónez A , John T. Speicher A , Christian Sebat B C D and Mark Avdalovic B CA Department of Anesthesiology and Pain Medicine, University of California Davis Health System, Sacramento, CA 95817, USA.
B Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California Davis Health System, Sacramento, CA 95817, USA.
C Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Mather VA Medical Center (NCHCS), Mather, CA 95655, USA.
D Corresponding author. Email: csebat@ucdavis.edu
Healthcare Infection 17(3) 83-86 https://doi.org/10.1071/HI12011
Submitted: 13 March 2012 Accepted: 19 June 2012 Published: 16 July 2012
Abstract
Invasive fungal infections are increasing in incidence, along with the use of immunosuppressive medications for the prevention of organ transplant rejection, graft versus host disease and treatment of auto-immune disorders. Additionally, the incidence of invasive fungal infections is increasing with the use of new antineoplastic therapies for malignancy, increasing incidence of diabetes mellitus, expanded use of broad-spectrum antimicrobial therapy and with an aging population with chronic medical problems such as chronic renal failure, chronic obstructive pulmonary disease and HIV. We present a case of primary cutaneous zygomycosis at the insertion site of a central venous catheter in a 45-year-old renal transplant patient admitted for acute pancreatitis. In the critical care setting, clinicians must retain a high index of suspicion for invasive fungal infections in immunocompromised individuals to ensure early diagnosis and provide aggressive medical and surgical intervention. Liposomal amphoterin B is the first line antimicrobial therapy, and reduction or discontinuation of immunosuppressive therapy should be considered. Currently there are no consensus opinions or recommendations for routine, scheduled replacement of central venous catheters to prevent infections, even in immunosuppressed patients.
References
[1] Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect 2009; 15 41–5.| Cutaneous zygomycosis.Crossref | GoogleScholarGoogle Scholar |
[2] Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al Epidemiology and outcome of zygomycosis: A Review of 929 Reported Cases. Clin Infect Dis 2005; 41 634–53.
| Epidemiology and outcome of zygomycosis: A Review of 929 Reported Cases.Crossref | GoogleScholarGoogle Scholar |
[3] Cuenca-Estrella M, Bernal-Martinez L, Isla G, Gomez-Lopez A, Alcazar-Fuoli L, Buitrago MJ. Incidence of zygomycosis in transplant recipients. Clin Microbiol Infect 2009; 15 37–40.
| Incidence of zygomycosis in transplant recipients.Crossref | GoogleScholarGoogle Scholar |
[4] Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock 2008; 1 106–13.
| Mucormycosis in immunochallenged patients.Crossref | GoogleScholarGoogle Scholar |
[5] Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6 2365–74.
| Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD28rksFCkug%3D%3D&md5=8d66eef022cce976e4888bfb9a633f8bCAS |
[6] Chakrabarti S, Chatterjee S, Das A, Panda N, Shivaprakash MR, Kaur A, et al Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009; 85 573–81.
| Invasive zygomycosis in India: experience in a tertiary care hospital.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1Mjkt1artg%3D%3D&md5=3d4ca6d6aefe2365baae9df363f1b935CAS |
[7] Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, et al Forty-one recent cases of invasive zygomycosis from global clinical registry. J Antimicrob Chemother 2010; 65 296–302.
| Forty-one recent cases of invasive zygomycosis from global clinical registry.Crossref | GoogleScholarGoogle Scholar |
[8] Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52 1556–8.
| Combination echinocandin-polyene treatment of murine mucormycosis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXksFajuro%3D&md5=34144b90d3b5f9a5b2528e546182ab2fCAS |
[9] Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al Posaconazole as salvage therapy in zygomycosis. Antimicrob Agents Chemother 2006; 50 126–33.
| Posaconazole as salvage therapy in zygomycosis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XivVGltA%3D%3D&md5=e1d06b98cc2a5a3bd33cd76630c96a00CAS |
[10] van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42 e61–5.
| Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XjtlGqsL0%3D&md5=ca4d5225089529ad7a0d9bf46c8dbd81CAS |
[11] Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61 i35–i40.
| Treatment of zygomycosis: current and new options.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXhs1CqsLo%3D&md5=580f6f35b2bdbbd752ca6bc4e0ed75d5CAS |
[12] Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51 2587–90.
| In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXnsVajs70%3D&md5=b48cb58fc96adc1211bbbc0b94780313CAS |
[13] Cook D, Randolph A, Kernerman P, Cupido C, King D, Soukup C, et al Central venous catheter replacement strategies: A systematic review of the literature. Crit Care Med 1997; 25 1417–24.
| Central venous catheter replacement strategies: A systematic review of the literature.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK2svhtFyntA%3D%3D&md5=9917e50d80405a33f7b596cf3888b3dbCAS |
[14] Timsit MJ. Scheduled replacement of central venous catheters is not necessary. Infect Control Hosp Epidemiol 2000; 21 371–4.
| Scheduled replacement of central venous catheters is not necessary.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3M%2FgvVOkuw%3D%3D&md5=ba32e9721c674c95ee05cea94c563473CAS |
[15] O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002; 23 759–69.
| Guidelines for the prevention of intravascular catheter-related infections.Crossref | GoogleScholarGoogle Scholar |
[16] Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters. Medicine 2002; 81 466–79.
| A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters.Crossref | GoogleScholarGoogle Scholar |
[17] Pearson ML, Guidelines for the Hospital Infection Control Practices Advisory Committee Guideline for the prevention of intravascular-device-related infections. Infect Control Hosp Epidemiol 1996; 17 438–73.
| Guideline for the prevention of intravascular-device-related infections.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK28vjs12rtQ%3D%3D&md5=90840f14c09d4760bd2799c522f18526CAS |
[18] Bach A, Stubbig K, Geiss H. Infectious risk of replacing venous catheters by the guide-wire technique. Zentralbl Hyg Umweltmed 1992; 193 150–9.
| 1:STN:280:DyaK3s%2FgtVehsw%3D%3D&md5=8976d3811d1beb0ae0bfc7dff391ccaaCAS |